Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform

Reuters2026/08/07 10:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cellectis outlined 4 ongoing allogeneic CAR-T clinical trials, including 2 pivotal Phase 2 studies and 2 Phase 1 studies.
Cash position of USD 169 million as of June 30, 2026; expected runway into Q4 2027.
Lasme-cel pivotal Phase 2 first interim analysis expected in Q4 2026; eti-cel Phase 1 full dataset expected in Q4 2026.
Presentation highlighted TALEN gene-editing platform positioning on safety, precision, efficiency, versatility.
Manufacturing footprint centered on Paris, France, and Raleigh, North Carolina, supporting end-to-end in-house production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform

You may also like

Crypto prices